Determinants of heterosexual men's demand for long-acting injectable pre-exposure prophylaxis (PrEP) for HIV in urban South Africa

被引:18
|
作者
Cheng, Chih-Yuan [1 ,2 ,3 ]
Quaife, Matthew [1 ]
Eakle, Robyn [4 ]
Escobar, Maria A. Cabrera [4 ]
Vickerman, Peter [5 ]
Terris-Prestholt, Fern [1 ]
机构
[1] London Sch Hyg & Trop Med, Fac Publ Hlth & Policy, 15-17 Tavistock Pl, London WC1H 9SH, England
[2] Heidelberg Univ, Med Fac Mannheim, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany
[3] German Canc Res Ctr, Div Hlth Econ, Neuenheimer Feld 280, D-69120 Heidelberg, Germany
[4] Univ Witwatersrand, Wits RHI, 22 Esselen St, ZA-2001 Johannesburg, South Africa
[5] Univ Bristol, Sch Social & Community Med, Canynge Hall,39 Whatley Rd, Bristol BS8 2PS, Avon, England
基金
英国经济与社会研究理事会;
关键词
HIV prevention; Long-acting injectable pre-exposure prophylaxis; Heterosexual men; South Africa; Biomedical strategies; ANTIRETROVIRAL PROPHYLAXIS; PREVENTION; INFECTION; SEX; RISK; PREFERENCES; TRANSMISSION; WILLINGNESS; PERCEPTIONS; TENOFOVIR;
D O I
10.1186/s12889-019-7276-1
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
BackgroundHeterosexual men in South Africa are a large key population to exposure to HIV, yet preferences for HIV pre-exposure prophylaxis (PrEP) among this population have not, to date, been investigated in the literature. This paper aims to explore HIV prevention preferences among heterosexual men in urban South Africa, as well as to examine the demand and characteristics of men who favour long-acting injectable (LAI) PrEP over condoms and oral PrEP.MethodsData were collected among 178 self-reported HIV-negative heterosexual men, who were given example products and information before being asked which they preferred. Multivariate logistic regression was used to analyse which characteristics were associated with product choice.Results48% (n=85) of participants preferred LAI PrEP, while 33% (n=58) and 20% (n=35) chose oral PrEP and condoms respectively. Having children (marginal effect=0.22; 95% CI [0.01, 0.44]) or having higher risk attitude scores (marginal effect=0.03; 95% CI [0.01, 0.06]) was significantly associated with a choice of LAI PrEP, while those who had unprotected anal intercourse (marginal effect=-0.42; 95% CI [-0.57, -0.27]) and those who were concerned with protection against other sexually transmitted infections over HIV (marginal effect=-0.42; 95% CI [-0.60, -0.24]) appeared less likely to prefer LAI PrEP.ConclusionsThe results suggested a relatively high demand and theoretical acceptability for LAI PrEP among heterosexual men in urban South Africa, but there appeared to be fewer distinct predictors for the willingness to use LAI PrEP compared to studies conducted among gay and bisexual men and women. Nevertheless, the findings contribute to the mapping of the demand and determinants of heterosexual men's preferences for novel antiretroviral-based prevention in sub-Saharan Africa, and the data could aid in the differentiated design of future HIV prevention strategies using LAI PrEP in conjunction with other methods.
引用
收藏
页数:9
相关论文
共 50 条
  • [11] M Long-Acting Injectable Preexposure Prophylaxis for HIV Prevention in South Africa: Is There a Will and a Way?
    Landovitz, Raphael J.
    Grinsztejn, Beatriz
    JOURNAL OF INFECTIOUS DISEASES, 2016, 213 (10) : 1519 - 1520
  • [12] Will Gay and Bisexual Men Taking Oral Pre-exposure Prophylaxis (PrEP) Switch to Long-Acting Injectable PrEP Should It Become Available?
    John, Steven A.
    Whitfield, Thomas H. F.
    Rendina, H. Jonathon
    Parsons, Jeffrey T.
    Grov, Christian
    AIDS AND BEHAVIOR, 2018, 22 (04) : 1184 - 1189
  • [13] Optimizing Uptake of Long-Acting Injectable Pre-exposure Prophylaxis for HIV Prevention for Men Who Have Sex with Men
    Lorraine T. Dean
    Zachary Predmore
    Alexandra Skinner
    Siena Napoleon
    Philip A. Chan
    Julia Raifman
    AIDS and Behavior, 2023, 27 : 2606 - 2616
  • [14] Exploring preferences and decision-making about long-acting injectable HIV pre-exposure prophylaxis (PrEP) among young sexual minority men 17-24 years old
    John, Steven A.
    Zapata, Juan P.
    Dang, Madeline
    Pleuhs, Benedikt
    O'Neil, Andrew
    Hirshfield, Sabina
    Walsh, Jennifer L.
    Petroll, Andrew E.
    Quinn, Katherine G.
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [15] Willingness of community-recruited men who have sex with men in Washington, DC to use long-acting injectable HIV pre-exposure prophylaxis
    Levy, Matthew E.
    Patrick, Rudy
    Gamble, Jonjelyn
    Rawls, Anthony
    Opoku, Jenevieve
    Magnus, Manya
    Kharfen, Michael
    Greenberg, Alan E.
    Kuo, Irene
    PLOS ONE, 2017, 12 (08):
  • [16] Long-acting HIV pre-exposure prophylaxis (PrEP) approaches: recent advances, emerging technologies, and development challenges
    Agrahari, Vivek
    Anderson, Sharon M.
    Peet, M. Melissa
    Wong, Andrew P.
    Singh, Onkar N.
    Doncel, Gustavo F.
    Clark, Meredith R.
    EXPERT OPINION ON DRUG DELIVERY, 2022, 19 (10) : 1365 - 1380
  • [17] Cost-Effectiveness of HIV Pre-exposure Prophylaxis Among Heterosexual Men in South Africa: A Cost-Utility Modeling Analysis
    Vogelzang, Michelle
    Terris-Prestholt, Fern
    Vickerman, Peter
    Delany-Moretlwe, Sinead
    Travill, Danielle
    Quaife, Matthew
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2020, 84 (02) : 173 - 181
  • [18] Conjoint Analysis of User Acceptability of Sustained Long-Acting Pre-Exposure Prophylaxis for HIV
    Schieffer, Robert J.
    Bryndza Tfaily, Ewa
    D'Aquila, Richard
    Greene, George J.
    Carballo-Dieguez, Alex
    Giguere, Rebecca
    Tagliaferri Rael, Christine
    Kiser, Patrick F.
    Hope, Thomas J.
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2022, 38 (04) : 336 - 345
  • [19] Statistical approaches to accelerate the development of long-acting antiretrovirals for HIV pre-exposure prophylaxis
    Glidden, David V.
    CURRENT OPINION IN HIV AND AIDS, 2020, 15 (01) : 56 - 60
  • [20] Potential effectiveness of long-acting injectable pre-exposure prophylaxis for HIV prevention in men who have sex with men: a modelling study
    Marshall, Brandon D. L.
    Goedel, William C.
    King, Maximilian R. F.
    Singleton, Alyson
    Durham, David P.
    Chan, Philip A.
    Townsend, Jeffrey P.
    Galvani, Alison P.
    LANCET HIV, 2018, 5 (09): : E498 - E505